Literature DB >> 9299438

Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations.

M Ohiwa1, H Murakami, T Iwashita, N Asai, Y Iwata, T Imai, H Funahashi, H Takagi, M Takahashi.   

Abstract

We analyzed the intracellular signalling pathway through Ret activated by glial-cell-line-derived neurotrophic factor (GDNF), multiple endocrine neoplasia (MEN) 2A and 2B mutations. The results showed that all of them induce a signal transducing complex consisting of Ret, Shc, and Grb2 proteins. In addition, GDNF clearly activated a Ras-MAPK pathway in human neuroblastoma cells. Rat is expressed mainly as two isoforms that differ in the carboxy-terminal sequence: a long isoform (1114 amino acids) and a short isoform (1072 amino acids). The long isoform contains the consensus sequence for binding of the Shc PTB domain but not of its SH2 domain, whereas the short isoform has the consensus sequences for binding of both domains. In vitro binding assay revealed that the long isoform of the MEN2A-Ret protein and both isoforms of the MEN2B-Ret protein bound preferentially to the Shc PTB domain. On the other hand, the short isoform of MEN2A-Ret bound to the PTB and SH2 domains. In neuroblastoma cells expressing both isoforms of Ret, its activation by GDNF also resulted in the binding of both domains. GDNF and MEN 2A mutations activate Ret by inducing its dimerization, whereas the MEN 2B mutation increases Ret catalytic activity without dimerization. Our results thus suggest that Ret dimerization might be required for binding of the Shc SH2 domain to the short isoform.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9299438     DOI: 10.1006/bbrc.1997.7225

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

Review 1.  Neurotrophic factors and their receptors in axonal regeneration and functional recovery after peripheral nerve injury.

Authors:  J Gordon Boyd; Tessa Gordon
Journal:  Mol Neurobiol       Date:  2003-06       Impact factor: 5.590

2.  A Drosophila model of multiple endocrine neoplasia type 2.

Authors:  Renee D Read; Paul J Goodfellow; Elaine R Mardis; Nancy Novak; Jon R Armstrong; Ross L Cagan
Journal:  Genetics       Date:  2005-06-18       Impact factor: 4.562

3.  Brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor are required simultaneously for survival of dopaminergic primary sensory neurons in vivo.

Authors:  J T Erickson; T A Brosenitsch; D M Katz
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

4.  Multiple actions of neurturin correlate with spatiotemporal patterns of Ret expression in developing chick cranial ganglion neurons.

Authors:  E Hashino; E M Johnson; J Milbrandt; M Shero; R J Salvi; C S Cohan
Journal:  J Neurosci       Date:  1999-10-01       Impact factor: 6.167

5.  Internalization of glial cell-derived neurotrophic factor receptor GFR alpha 1 in the absence of the ret tyrosine kinase coreceptor.

Authors:  P Vieira; J Thomas-Crusells; A Vieira
Journal:  Cell Mol Neurobiol       Date:  2003-02       Impact factor: 5.046

6.  Differential activities of the RET tyrosine kinase receptor isoforms during mammalian embryogenesis.

Authors:  E de Graaff; S Srinivas; C Kilkenny; V D'Agati; B S Mankoo; F Costantini; V Pachnis
Journal:  Genes Dev       Date:  2001-09-15       Impact factor: 11.361

Review 7.  Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis.

Authors:  J R Hansford; L M Mulligan
Journal:  J Med Genet       Date:  2000-11       Impact factor: 6.318

8.  A targeting mutation of tyrosine 1062 in Ret causes a marked decrease of enteric neurons and renal hypoplasia.

Authors:  Mayumi Jijiwa; Toshifumi Fukuda; Kumi Kawai; Akari Nakamura; Kei Kurokawa; Yoshiki Murakumo; Masatoshi Ichihara; Masahide Takahashi
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

9.  Phosphotyrosine 1062 is critical for the in vivo activity of the Ret9 receptor tyrosine kinase isoform.

Authors:  Adrianne Wong; Silvia Bogni; Pille Kotka; Esther de Graaff; Vivette D'Agati; Frank Costantini; Vassilis Pachnis
Journal:  Mol Cell Biol       Date:  2005-11       Impact factor: 4.272

Review 10.  Recent advances in the biology and therapy of medullary thyroid carcinoma.

Authors:  Barry Nelkin
Journal:  F1000Res       Date:  2017-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.